HIV Type 1 Vaccine-Induced Cytotoxic T Cell Responses in Phase I Clinical Trials: Detection, Characterization, and Quantitation

1997 ◽  
Vol 13 (3) ◽  
pp. 211-216 ◽  
Author(s):  
M. JULIANA McELRATH ◽  
ROBERT F. SILICIANO ◽  
KENT J. WEINHOLD
Keyword(s):  
Clinical Trials ◽  
T Cell ◽  
Phase I ◽  
T Cell Responses ◽  
Cytotoxic T Cell ◽  
Phase I Clinical Trials ◽  
Cell Responses ◽  
Hiv Type 1 ◽  
Cytotoxic T Cell Responses

Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children

1991 ◽  
Vol 119 (2) ◽  
pp. 230-236 ◽  
Author(s):  
Katherine Luzuriaga ◽  
Richard A. Koup ◽  
Cheryl A. Pikora ◽  
Doreen B. Brettler ◽  
John L. Sullivan
Keyword(s):  
Human Immunodeficiency Virus ◽  
T Cell ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
T Cell Responses ◽  
Cytotoxic T Cell ◽  
Cell Responses ◽  
Immunodeficiency Virus ◽  
Cytotoxic T Cell Responses

scholarly journals HIV mRNA Vaccines—Progress and Future Paths

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 134
Author(s):  
Zekun Mu ◽  
Barton F. Haynes ◽  
Derek W. Cain
Keyword(s):  
T Cell ◽  
Neutralizing Antibodies ◽  
Vaccination Strategy ◽  
T Cell Responses ◽  
Neutralizing Antibody ◽  
Cytotoxic T Cell ◽  
Therapeutic Vaccines ◽  
Cell Responses ◽  
Broadly Neutralizing Antibody ◽  
Cytotoxic T Cell Responses

The SARS-CoV-2 pandemic introduced the world to a new type of vaccine based on mRNA encapsulated in lipid nanoparticles (LNPs). Instead of delivering antigenic proteins directly, an mRNA-based vaccine relies on the host’s cells to manufacture protein immunogens which, in turn, are targets for antibody and cytotoxic T cell responses. mRNA-based vaccines have been the subject of research for over three decades as a platform to protect against or treat a variety of cancers, amyloidosis and infectious diseases. In this review, we discuss mRNA-based approaches for the generation of prophylactic and therapeutic vaccines to HIV. We examine the special immunological hurdles for a vaccine to elicit broadly neutralizing antibodies and effective T cell responses to HIV. Lastly, we outline an mRNA-based HIV vaccination strategy based on the immunobiology of broadly neutralizing antibody development.

Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?

2005 ◽  
Vol 18 (4) ◽  
pp. 234-242 ◽  
Author(s):  
Silvia Garbelli ◽  
Stefania Mantovani ◽  
Belinda Palermo ◽  
Claudia Giachino
Keyword(s):  
T Cell ◽  
T Cell Responses ◽  
Cytotoxic T Cell ◽  
Cell Responses ◽  
Cytotoxic T Cell Responses

Cytotoxic T Cell Responses against Mesothelioma by Apoptotic Cell-pulsed Dendritic Cells

2004 ◽  
Vol 169 (12) ◽  
pp. 1322-1330 ◽  
Author(s):  
Frédéric Ebstein ◽  
Carole Sapede ◽  
Pierre-Joseph Royer ◽  
Marie Marcq ◽  
Catherine Ligeza-Poisson ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Apoptotic Cell ◽  
T Cell Responses ◽  
Cytotoxic T Cell ◽  
Cell Responses ◽  
Cytotoxic T Cell Responses
Sign in / Sign up

Export Citation Format

Share Document